đź“° Full Story
Kailera Therapeutics raised $625 million in an initial public offering and began trading on Nasdaq on April 17, 2026 under the ticker KLRA. The biotech sold roughly 39.06 million shares at $16 each and the stock opened at $26, a surge of about 62.5% from the offering price.
The deal, one of the largest biotech IPOs in recent years, pushed the company’s valuation into the low billions after the first-day pop.
Kailera is developing multiple GLP-1–class obesity treatments, including a global Phase 3 injectible GLP-1/GIP candidate and an oral GLP-1 program; key late-stage readouts for the lead program are not expected until 2028.
Backers include prominent venture investors such as Bain Capital, Atlas Venture and Arch Venture Partners.
The listing underscores strong investor appetite for obesity drugs as established players like Novo Nordisk and Eli Lilly dominate a market projected to reach roughly $150 billion annually by the end of the decade.







đź’¬ Commentary